Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.
about
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaDasatinib as a treatment for Duchenne muscular dystrophyStructural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainDiscovery of Diverse Small-Molecule Inhibitors of Mammalian Sterile20-like Kinase 3 (MST3)Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.SRC: a century of science brought to the clinic.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.An update on dual Src/Abl inhibitors.Control of mammary tumor differentiation by SKI-606 (bosutinib).Pharmacological targeting of the pseudokinase Her3Development of small molecules targeting the pseudokinase Her3.A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.TSLP signaling network revealed by SILAC-based phosphoproteomicsDual tyrosine kinase inhibitors in chronic myeloid leukemia.Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasisAdvances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.Functions of Fyn kinase in the completion of meiosis in mouse oocytes.Localized activation of Src-family protein kinases in the mouse egg.20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism.Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.Fyn kinase activity is required for normal organization and functional polarity of the mouse oocyte cortex.Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.Development of an effective therapy for chronic myelogenous leukemiaSignalling pathways passing Src in pancreatic endocrine tumours: relevance for possible combined targeted therapies.Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.Bosutinib in the management of chronic myelogenous leukemia.Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.Targeting Fyn Kinase in Alzheimer's Disease.Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors.Bosutinib for Chronic Myeloid Leukemia.Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases.Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction.4-Aryl-4H-naphthopyrans derivatives: one-pot synthesis, evaluation of Src kinase inhibitory and anti-proliferative activities.
P2860
Q24607114-BDA2578D-6775-4818-9588-B42120FDCA0FQ27300846-AA0B79B7-55CE-4114-A0A0-B9A982CD3297Q27678454-B27C95D7-CC71-4401-9528-0A0BCBB74FB3Q27704783-E0308A4B-B769-46F1-A0A3-C12A858168BAQ27712065-7293F38C-7F08-42C7-A2ED-B5777C45EA0FQ33335166-1A3BFDE6-B25F-441D-8745-E2935D4AC3ECQ34041298-44315957-499C-4028-9D03-9B7C8C39E629Q34121339-EB5E3326-F275-4989-8D4E-810EFE8DA9C6Q34270677-060F373D-EB88-4F1C-9FAE-3245C03AB666Q34398204-ED5A489E-BC71-4B88-A859-C64F1BFE6EEBQ34514043-3F1B52FA-F077-43C6-8A69-C21033CD115AQ35669652-0F89CE8B-C0E5-4A8C-BF87-28EA39881272Q35915123-EB74D181-0D88-4C64-AD18-BE5C8105F2B6Q36208936-7638D7EA-3070-4D3D-9778-74F53DDDED3DQ36265601-22174139-5273-4000-BDB4-E2368F0594D4Q36322698-BD6996C6-2DDB-40E6-B612-337E2A2D983EQ36600241-330C839C-500B-4FA3-B838-AB8C4C5D1A35Q37114289-53FB97D8-5634-4F43-8E30-FA8B1A5D32DDQ37223421-09FD5CD1-2575-47EC-BA46-0668C60C5087Q37337330-3245A774-A4DD-41DF-A495-305C14FCB7E0Q37702115-2CB42855-17E6-4DE5-928B-F687DD7F43CBQ37726977-7F023C96-0042-485A-8B8B-97F5964B5444Q37810115-83A1B197-6BC6-498E-A5EA-2B029CE6B43EQ37918304-C823B568-5210-4541-9FFF-D99B27089204Q37966917-E16EDFF6-1641-44C2-9849-0C9E1F668E36Q37996268-EE5677A3-33C7-41CD-B787-DA23ECC4CB11Q38055491-835883AC-5DF2-41B6-9D7F-AD655C66B96DQ38068109-EA079CEF-3F4F-4C39-A3B0-CA4DF4049511Q38106952-98E51883-8DA5-4B61-BFDC-2BA0EB127D84Q38183422-73084F6B-5EE1-4CBD-A7C0-6DE58F275D0BQ38678555-6E56D099-C131-4FC9-AEB6-C029FBA49E44Q38817367-1D55EB3A-D071-48BE-A98A-D5275A55D598Q38818048-BFE216CA-F148-4FD3-971D-0158592ED4DAQ38823850-90BB9151-0D62-452F-9021-15B4A3C60341Q38835127-C1516072-153A-4DA9-B5D5-589D308128CBQ38972808-89E7432F-9E87-41C2-86C7-3FFF64BAE987Q40529563-05A72218-6925-4DF5-90DF-B7F6BC8B56AEQ40630924-4CFC38F7-0E58-458B-BA24-DF15FDD169F9Q40643967-0EC01005-0104-4ACB-99B3-F6C1F0606237Q41050465-961799DC-46A0-49A6-A43A-AF1DF7D218BA
P2860
Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Optimization of 4-phenylamino- ...... bitors of Src kinase activity.
@en
type
label
Optimization of 4-phenylamino- ...... bitors of Src kinase activity.
@en
prefLabel
Optimization of 4-phenylamino- ...... bitors of Src kinase activity.
@en
P2093
P356
P1476
Optimization of 4-phenylamino- ...... bitors of Src kinase activity.
@en
P2093
Boschelli DH
Boschelli F
Discafani C
Johnson SL
P304
P356
10.1021/JM0102250
P407
P577
2001-11-01T00:00:00Z